March 2nd 2023
The FDA has planned a regular review of the biologic license application for cosibelimab for the treatment for metastatic or locally advanced cutaneous squamous cell carcinoma.
January 5th 2023
Hamid Reviews Options for Patients With Basal Cell Carcinoma and Cutaneous Squamous Cell CarcinomaNovember 10th 2022
During a Targeted Oncology case-based roundtable event, Omid Hamid, MD, discussed the data supporting the use of hedgehog pathway inhibitors and immunotherapies for skin cancers.
Bexmarilimab Derives Overall Survival Benefit in PD-1 Blockade Refractory MelanomaOctober 19th 2022
Results from the melanoma cohort of the phase 1/2 MATINS show the potential of bexmarilimab monotherapy and combined with other immunotherapies across solid tumors and hematologic malignancies.
Sequential Immunotherapy and Targeted Therapy Shows OS Benefit in BRAF+ MelanomaOctober 12th 2022
Three different sequencing schemas for immunotherapy followed by targeted therapy in patients with BRAF V600-mutant melanoma have shown positive survival outcomes and safety consistent with results from prior studies.
IO Before BRAK/MEK Inhibition Is the Ideal Treatment Sequence for BRAF-Mutant MelanomaOctober 11th 2022
Data from the DREAMseq trial have answered a lingering question of how to sequence therapy for patients with advanced BRAF-mutant melanoma. This research supports immunotherapy in the first-line setting, followed by BRAK/MEK inhibitors.
Promising Pathologic Complete Response Elicited With Neoadjuvant Cemiplimab in CSCCSeptember 12th 2022
Neoadjuvant cemiplimab showed promising results in cutaneous squamous cell carcinoma with a near or complete disappearance of disease in almost 64% of patients set to undergo surgery.
CR Achieved in All Patients With Cutaneous BCC Given High-Dose STP705September 5th 2022
A cohort of a clinical trial of the experimental agent STP705 successfully treated patients with cutaneous basal cell carcinomas, offering an alternative to surgery or other skin cancer treatment.
Atezolizumab Triplet Induces Intracranial Responses in BRAF V600-Mutated Metastatic MelanomaSeptember 5th 2022
In patients with BRAF V600-mutated melanoma and central nervous system metastases, treatment with atezolizumab to vemurafenib plus cobimetinib achieved a good intracranial overall response rate. Responses were all achieved with the combination in patients with BRAF wild-type tumors.
Encorafenib/Binimetinib Outperforms BRAF Inhibitor Monotherapy in BRAF V600+ MelanomaJuly 26th 2022
Long-term follow-up in the COLUMBUS study shows continued survival improvement with encorafenib plus binimetinib and impressive disease control in patients with BRAF V600-mutant melanoma.
Detecting and Addressing Hard-to-Find Skin CancersJuly 14th 2022
Niraj H. Mehta, MD, reviews the areas of the body where skin cancer can be hard to detect, what the skin cancer will look like on those parts of the body, risk factors for those receiving treatment, and follow-up for patients to catch recurrences.
Recommended Phase 2 Dose of Tebentafusp Shows Promise in Metastatic Uveal MelanomaJune 17th 2022
A manageable side-effect profile, signal of efficacy, and 36% increase in the recommended phase 2 dose (RP2D) was seen with a step-up dosing regimen of tebentafusp in patients with metastatic uveal melanoma.
Increased Risk of Skin Cancer Seen in Military VeteransMay 19th 2022
For military veterans, future research should be accompanied by systematic efforts to improve skin cancer prevention, treatment, and outcomes among military service members and veterans, according to Carolyn J. Heckman, PhD.
Spartalizumab With Dabrafenib and Trametinib Shows Modest Efficacy in BRAF V600+ Metastatic MelanomaMay 5th 2022
The phase 3 COMBI-i trial demonstrated that spartalizumab plus dabrafenib and trametinib has modest efficacy in BRAF V600-positive metastatic melanoma, but no progression-free survival benefit when compared with dabrafenib and trametinib alone.
ADAPT-IT Raises Question About 4-Dose Schedule of Nivo/Ipi in Patients With Metastatic MelanomaApril 8th 2022
Efficacy and toxicity of standard four dose nivolumab and ipilimumab induction therapy in melanoma to be likely driven by the first 2 doses as demonstrated in the Adaptively Dosed ImmunoTherapy Trial.
PIVOT IO-001 Enrollment Stops After Trial Failure, But Analyses ContinueMarch 15th 2022
In PIVOT IO-001, patients with metastatic melanoma are no longer being enrolled and treatment arms have been unblinded after the combination of bempegaldesleukin and nivolumab did not meet its coprimary end points.
Roundtable Discussion: Atlas Considers Sequencing for a Patient With Basal Cell CarcinomaFebruary 17th 2022
During a Targeted Oncology case-based roundtable event, Jennifer L. Atlas, MD, discussed the case of a patient with infiltrative basal cell carcinoma with participants.